Rankings
▼
Calendar
RXRX Q3 2022 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RXRX
Recursion Pharmaceuticals, Inc.
$2B
Q3 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$13M
+422.1% YoY
Gross Profit
-$2M
-18.0% margin
Operating Income
-$63M
-479.4% margin
Net Income
-$60M
-463.1% margin
EPS (Diluted)
$-0.34
QoQ Revenue Growth
+70.6%
Cash Flow
Operating Cash Flow
-$55M
Free Cash Flow
-$63M
Stock-Based Comp.
$9M
Balance Sheet
Total Assets
$612M
Total Liabilities
$223M
Stockholders' Equity
$388M
Cash & Equivalents
$455M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$13M
$3M
+422.1%
Gross Profit
-$2M
$3M
-194.2%
Operating Income
-$63M
-$46M
-34.8%
Net Income
-$60M
-$47M
-27.4%
Revenue Segments
License and Service
$13M
99%
Grant
$107,000
1%
← FY 2022
All Quarters
Q4 2022 →